Sign inCreate account

Report workspace tools

NCT01745757COMPLETEDanonymous

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer

Sponsor

Source record

UNICANCER

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Metastatic Breast Cancer

Indication / condition

AI-normalized

Metastatic

Intervention

Source record

Bevacizumab, paclitaxel

Source & freshness

Source record

NCT ID

NCT01745757

Original source

ClinicalTrials.gov

Source last updated

Jan 27, 2023

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01745757

Title

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer

Sponsor

UNICANCER

Status

COMPLETED

Phase

Observational

Condition raw

Metastatic

Condition normalized

Metastatic

Modality raw

Metastatic

Modality normalized

monoclonal antibody

Target raw

Metastatic Breast Cancer

Target normalized

Metastatic Breast Cancer

Interventions

Bevacizumab, paclitaxel

Public preview

Source record

The COMET study, sponsored by UNICANCER, aimed to validate predictive factors and biological imaging related to the response of metastatic breast cancer patients to Bevacizumab and Paclitaxel. The study enrolled 510 patients and was completed in December 2022. It focused on identifying biomarkers that could help tailor treatments and improve patient outcomes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01745757

Status

COMPLETED

Phase

Observational

Sponsor

UNICANCER

Executive brief

Investment-Ready Snapshot

The COMET study, sponsored by UNICANCER, aimed to validate predictive factors and biological imaging related to the response of metastatic breast cancer patients to Bevacizumab and Paclitaxel. The study enrolled 510 patients and was completed in December 2022. It focused on identifying biomarkers that could help tailor treatments and improve patient outcomes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 27, 2023
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01745757

Indication

Metastatic

Modality

monoclonal antibody

Target

Metastatic Breast Cancer

Intervention

Bevacizumab, paclitaxel

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.